More than 90% of patients are able to be cured using the currently available treatments for chronic hepatitis C virus infection. In coming days, more armors will be added to the arsenal of HCV therapy. This publication synopsis summarizes the outcome of HCV-TARGET trial for the safety and efficacy of sofosbuvir plus ribavirin regime in HCV GT-2 infected patients. Chronic infection with HCV is a major cause of end-stage liver disease and hepatocellular carcinoma.
Sustained virological response 12 weeks post therapy (SVR12) is associated with a decreased risk of liver-related morbidity and mortality. Among the seven HCV genotypes (GTs) isolated until now, HCV genotype 2 (GT2) is the third most common GT with an estimated 16.5 million GT2-infected persons worldwide. Background Due to a high efficacy in clinical trials, the all-oral combination of sofosbuvir (SOF) and ribavirin (RBV) for…
